Skip to Content

A new cereblon E3 ligase modulator shows promising results with complete response in highly refractory multiple myeloma patients

At EHA 2021, Professor Sagar Lonial from the Winship Cancer Institute, Atlanta, presented results from an ongoing Phase 1/2 study in patients with relapsed/refractory multiple myeloma, treated with immunomodulatory drug iberdomid. This paves the way for phase III combination studies.

Bone Marrow Aspirate Cytology Of Multiple Myeloma

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top